Abstract 7354: ETS1 orchestrates a hybrid EMT program to drive metastasis and immune evasion in UASCC
Abstract Intratumoral transcriptional heterogeneity (ITH) is a defining feature of aggressive cancers, yet the mechanisms by which distinct ITH programs drive metastasis and immune escape in upper aerodigestive squamous cell carcinoma (UASCC) remain poorly understood. Using single-cell RNA sequencing of cancer cell lines and patient tumors, we identified a hybrid epithelial-mesenchymal transition (hEMT) program strongly associated with metastatic potential. We determined that the transcription factor ETS1 functions as a master regulator of this hEMT state, directly activating pro-invasive and pro-metastatic gene networks and promoting distant dissemination in vivo. Beyond its role in metastasis, ETS1 unexpectedly established an immune-cold microenvironment by transcriptionally inducing STAT1 and PD-L1 (CD274), leading to reduced T-cell infiltration and elevated immune checkpoint expression. Clinically, ETS1-high tumors were consistently linked to poor survival and diminished responses to immune checkpoint blockade across multiple independent cohorts. Through a focused drug screen, we found that ETS1-high cancers exhibit selective vulnerability to HSP90 inhibition (e.g., Alvespimycin), which reduces ETS1 expression via disruption of HIF1A-driven transcription. Together, these findings define ETS1 as a central driver of both metastatic progression and immune evasion in UASCC and nominate HSP90 inhibitors as a promising therapeutic strategy for ETS1-driven disease states. Citation Format: Chehyun Nam, Talia Wenger, Benjamin Ziman, Daniel Arnaudov, Thomas Tilton, Ethan Pan, Young Min Park, Uttam K. Sinha, De-Chen Lin1.. ETS1 orchestrates a hybrid EMT program to drive metastasis and immune evasion in UASCC [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2026; Part 1 (Regular Abstracts); 2026 Apr 17-22; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2026;86(7 Suppl):Abstract nr 7354.
Authors
- Benjamin Ziman (ORCID: https://orcid.org/0000-0003-0951-3534)
- Chehyun Nam (ORCID: https://orcid.org/0000-0001-8604-2313)
- Talia A. Wenger (ORCID: https://orcid.org/0000-0001-6616-2780)
- D Arnaudov
- Thomas Tilton
- De-Chen Lin1.
- Ethan Pan
- Young Min Park
Institutions
- University of Southern California (US)
- Yonsei University (KR)
- Keck Hospital of USC (US)
- Kaiser Permanente Walnut Creek Medical Center (US)
Publication Details
- Journal
- Cancer Research
- Published
- 2026-04-03
- DOI
- https://doi.org/10.1158/1538-7445.am2026-7354
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 0.00